OMass Raises $310 Million for Endocrine and Immune Programs
OMass Therapeutics closed an oversubscribed $310 million Series C, one of the largest private biotechnology rounds of 2026, to advance small-molecule programs in endocrinology and immunology. Bain Capital Life Sciences, Forbion and Novo Holdings…
